The quality control theory of aging

Area of Science:

• Gerontology
• Cellular Biology
• Pharmacology

Background:

• Aging is characterized by a decline in cellular quality control (QC) systems essential for maintaining homeostasis.
• Four key QC systems implicated in aging include endoplasmic reticulum (ER) protein processing, histone deacetylase (HDAC) activity, AMP-activated protein kinase (AMPK) nutrient sensing, and beta-adrenergic receptor (BAR) signaling.
• Dysregulation of these QC systems contributes to age-related functional decline and chronic diseases.

Purpose of the Study:

• To propose and validate the Quality Control (QC) theory of aging.
• To investigate the potential of reprogramming cellular QC systems for increased lifespan and improved health.
• To explore a pharmacological approach using existing drugs to target multiple aging pathways simultaneously.

Main Methods:

• The study proposes a pharmacological strategy to test the QC theory of aging.
• Utilizes three FDA-approved drugs: phenylbutyric acid (ER/HDAC modulator), metformin (AMPK activator), and propranolol (BAR inhibitor).
• Focuses on combination therapy to target multiple QC systems concurrently.

Main Results:

• The QC theory posits that aging results from reduced efficiency in cellular QC systems.
• Targeting these systems, particularly with drug combinations, offers a rational strategy to combat aging.
• Combination therapy is hypothesized to be more effective than single-drug treatments for aging-related decline.

Conclusions:

• Reprogramming key cellular QC systems presents a viable strategy for enhancing healthspan and lifespan.
• Combination pharmacotherapy targeting ER, HDAC, AMPK, and BAR pathways holds promise for preventing, delaying, or reversing age-related chronic diseases.
• This approach could significantly reduce the health burden associated with aging in society.